PrEP for HIV and STIs Prevention
(CAMELLIA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Pre-exposure prophylaxis (PrEP) is an important biomedical human immunodeficiency virus (HIV) prevention tool and may particularly benefit black, cis and trans-gender women, who are at an increased risk for HIV and Sexually Transmitted Infections (STIs). The purpose of this study is to use a population-based approach to create a cohort of cis and trans-gender women at risk for future HIV acquisition to better understand the factors associated with the risk of STIs and HIV diagnosis and predictors of PrEP use.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is PrEP safe for humans?
How does PrEP differ from other HIV prevention drugs?
What data supports the effectiveness of the drug Camelia Cohort for HIV and STIs prevention?
Research shows that HIV pre-exposure prophylaxis (PrEP) is effective in reducing HIV incidence and has high retention rates in clinical settings, which suggests that similar treatments like Camelia Cohort could also be effective. Additionally, studies indicate that PrEP users often receive appropriate preventive care, such as immunizations and STI testing, which supports its overall effectiveness in real-world settings.2591011
Who Is on the Research Team?
Latesha Elopre, MD, MSPH
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This study is for cis and trans-gender women aged 18-50 living in Alabama who have had an STI recently but are currently HIV negative, gonorrhea and syphilis free, and own a private smartphone.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Enrollment and Baseline Assessment
Participants are enrolled and baseline data is collected using a mobile health app
Longitudinal Follow-up
Participants are followed longitudinally to assess factors associated with STI/HIV infection and PrEP use
Follow-up
Participants are monitored for safety and effectiveness after the main study period
What Are the Treatments Tested in This Trial?
Interventions
- Camelia Cohort
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator